• Latest Posts

Hasten raises $315M for acquisitions and pipeline development

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study

Likang gets trial ok for China’s first personalized cancer vaccine 

Could changing mRNA provide a new target for Alzheimer’s disease?


Porton and DanausGT look to boost development of gene and cell therapy

Biocytogen launches nanobody therapeutics project for 100 targets

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

Lifesciences and biotech in 2023

Cartherics granted first patent in China